Repligen Corp. (NASDAQ: RGEN) closed the day trading at $183.92 down -0.45% from the previous closing price of $184.75. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 337956 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of RGEN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 136.89. For the most recent quarter (mrq), Quick Ratio is recorded 5.75 and its Current Ratio is at 7.02. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.32.
On July 20, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $185.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when KURIYEL RALF sold 3,517 shares for $193.73 per share. The transaction valued at 681,348 led to the insider holds 24,260 shares of the business.
Hunt Anthony sold 16,707 shares of RGEN for $3,298,632 on Mar 08 ’24. The Chief Executive Officer now owns 185,249 shares after completing the transaction at $197.44 per share. On Feb 27 ’24, another insider, DAWES KAREN A, who serves as the Director of the company, sold 1,000 shares for $193.35 each. As a result, the insider received 193,350 and left with 87,367 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 10.30B and an Enterprise Value of 10.26B. As of this moment, Repligen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 255.20, and their Forward P/E ratio for the next fiscal year is 88.60. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 14.21. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.06 while its Price-to-Book (P/B) ratio in mrq is 5.20. Its current Enterprise Value per Revenue stands at 16.06 whereas that against EBITDA is 76.48.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.02, which has changed by 8.95% over the last 52 weeks, in comparison to a change of 27.86% over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $211.13, while it has fallen to a 52-week low of $110.45. The 50-Day Moving Average of the stock is 193.72, while the 200-Day Moving Average is calculated to be 168.30.
Shares Statistics:
Over the past 3-months, RGEN traded about 548.00K shares per day on average, while over the past 10 days, RGEN traded about 399.82k shares per day. A total of 55.77M shares are outstanding, with a floating share count of 51.97M. Insiders hold about 6.82% of the company’s shares, while institutions hold 104.77% stake in the company. Shares short for RGEN as of Mar 15, 2024 were 4.77M with a Short Ratio of 8.70, compared to 5.35M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.55% and a Short% of Float of 9.66%.
Earnings Estimates
Current recommendations for the stock of the company come from 12 analysts. On average, analysts expect EPS of $0.3 for the current quarter, with a high estimate of $0.34 and a low estimate of $0.26, while EPS last year was $0.64. The consensus estimate for the next quarter is $0.33, with high estimates of $0.37 and low estimates of $0.29.
Analysts are recommending an EPS of between $1.49 and $1.42 for the fiscal current year, implying an average EPS of $1.45. EPS for the following year is $2.08, with 11 analysts recommending between $2.35 and $1.85.
Revenue Estimates
12 analysts predict $150.06M in revenue for the current quarter. It ranges from a high estimate of $154.64M to a low estimate of $146M. As of the current estimate, Repligen Corp.’s year-ago sales were $182.66M, an estimated decrease of -17.80% from the year-ago figure.
A total of 12 analysts have provided revenue estimates for RGEN’s current fiscal year. The highest revenue estimate was $644.4M, while the lowest revenue estimate was $628M, resulting in an average revenue estimate of $636.48M. In the same quarter a year ago, actual revenue was $638.76M, down -0.40% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $740.56M in the next fiscal year. The high estimate is $785.8M and the low estimate is $718M. The average revenue growth estimate for next year is up 16.40% from the average revenue estimate for this year.
